THERAPEUTIC INDICATIONSEpipen Jr. auto injectors are automatic injection devices that contain adrenaline for allergic emergencies. The automatic injector is designed for children with a body weight of 7.5-25 kg. Automatic injectors should only be used by a person with a history or recognized risk of an anaphylactic reaction. Automatic injectors are indicated in the emergency treatment of allergic reactions (anaphylaxis) to insect bites or stings, food, drugs and other allergens, as well as idiopathic or exercise induced anaphylaxis. These reactions can occur minutes after exposure and consist of redness, apprehension, syncope, tachycardia, chronic or unreachable pulse associated with a drop in blood pressure, seizures, vomiting, diarrhea and abdominal cramps, involuntary urination, wheezing, spastic dyspnea Laryngeal, itching, rash, urticaria or angioedema.
0 Comments
INDICATIONSEpinephrine is indicated for the emergency treatment of allergic reactions (anaphylaxis) to insect bites and stings, food, medications and other allergens, as well as for idiopathic or exercise induced anaphylaxis. The EpiPen and EpiPen Jr autoinjectors are designed for the immediate self-administration of persons with a history of anaphylactic reactions. Such reactions may occur within minutes of exposure and consist of redness, apprehension, syncope, tachycardia, filiform or undetectable pulse associated with a drop in blood pressure, convulsions, vomiting, abdominal cramps and diarrhea, involuntary evacuation, wheezing, dyspnoea Due to pharyngeal spasm, pruritus, rashes, urticaria or angioedema. EpiPen and EpiPen Jr should only be used as emergency supportive therapy and do not replace or replace immediate medical or hospital care.
DOSAGETreatment with tolvaptan should be initiated at a dose of 15 mg once daily. The dose may be increased to a maximum of 60 mg once daily as tolerated to achieve the desired serum sodium level. During dose adjustment, both serum sodium and the controversial condition of the patients should be monitored. If there is no adequate increase in serum sodium levels, other treatment options should be considered either in place of tolvaptan or as an adjuvant treatment. In patients who achieve an adequate increase in serum sodium levels, they should monitor the underlying disease and serum sodium levels at regular intervals to assess whether tolvaptan treatment is necessary. In the context of hyponatremia, the duration of treatment is determined by the underlying disease and its treatment. Treatment with tolvaptan is expected to continue until the underlying disease has been adequately treated or until hyponatraemia is no longer a clinical problem.
APPLICATION AREAS Intended area of application for this filter is the infusion therapy. It is to be used for the filtration on infusion solutions, protection against the contamination through bacteria, fungi, microorganisms and endotoxins up to 120h, to emit air bubbles and hold back extraneous particles. Commercial infusion sets and connection tubings with luer-lock-fittings can be connected.
APPLICATION AREASIntended area for application for this filter is the infusion therapy. It is to be used for the filtration of infusion solutions, protection against the contamination through bacteria, fungi, microorganisms and endotoxins, to emit air bubble and hold back extraneous particles. Commercial infusion sets and connection tubings with luer-lock-fittings can be connected.
Product FeaturesThe mechanism of action of HAMSYL is based on the selective killing of leukemic cells due to depletion of plasma asparagine. Some leukemic cells are unable to synthesize asparagine due to a lack of asparagine synthetase and depend on an exogenous source of asparagine for survival. The depletion of asparagine, which results from treatment with the enzyme L-asparaginase, kills the leukemic cells. Normal cells, however, are less affected by depletion because of their ability to synthesize asparagine.
THERAPEUTIC INDICATIONSDantrolene Intravenous is indicated as an appropriate supportive measure for the management of fulminant hypermetabolism of skeletal muscle characteristic of the Malignant Hypertemia crisis. This should be administrative by intravenous injection as soon as the reaction of Maltemia Hypertemia is recognized.
ALL General Leukemia Incidence Varies by Age Total childhood cancer age-specific incidence rates by leukemia versus non-leukemia, all races, both sexes, SEER, 1986-94 Pediatric SEER Monograph. Leukemia. National Cancer Institute. 1. Smith M. A. et al. National Cancer Institute. SEER Pediatric Monograph. 17-34. “Below age 15 the national ALL mortality rate has declined dramatically, from 14.6 to 3.7 deaths per year per million from 1970 to 2004 and from 800+ deaths in 1970 to an average of 220 deaths per year during 2000-2004. In 1970, 15-24 year-olds had one-third the ALL death rate and one-third the number of deaths that occurred in younger patients. Since 1995, 15-19 and 20-24 year-olds have had a greater death rate than younger patients and the highest of all 5-year age groups younger than 55 years. The number of deaths from ALL has become higher in 15-24 year-olds than in any other 10-year age group”.1 A major unanswered question about ALL is why some patients have better outcomes than others. Various factors predict outcome and include: Patient characteristics
Influencing Factors of ALL Therapy 1 1. Gokbuget, N. et al. Hematology 2006;2006:133-141
CR = Complete Remission The mechanism of action of Asparaginase Pegilada is based on the selective killing of leukemic cells due to depletion of plasma asparagine. Some leukemic cells are unable to synthesize asparagine due to lack of asparagine synthetase and are dependent on an exogenous source of asparagine for survival. Asparagine depletion, resulting from treatment with the enzyme L-asparaginase, kills leukemia cells. Normal cells, however, are less affected by the depletion due to their ability to synthesize asparagine. Asparaginase Pegilada administered to patients with ALL, as part of a treatment regimen of multiagent chemotherapy. L-asparaginase was first approved in 1978 as a treatment for ALL. Asparaginase therapy has been an important part of treatment of multi-agent chemotherapy of ALL for over 30 years. In 1994, the FDA approved the only pegylated asparaginase formulation, called Asparaginase Pegilada . Asparaginasa Pegilada is composed by the derivative of E. coli L-asparaginase, which are synthetically modified by covalent conjugation monomethoxypolyethylene units (PEG) to the enzyme. Pegylation of the L - asparaginase allows Asparaginase Pegilada to provide sustained and prolonged effect duration compared with E. coli native L-asparaginase. Furthermore, Asparaginase Pegilada can be administered to patients with known hypersensitivity to E. coli L-asparaginase native. -------- History of the Development of the use of asparaginase --------- Asparaginase Pegilada depletion achieved in 90% of patient samples. 1 * 1 * Treatment for Children's Cancer Group 1962 deferred no intensification. 1 and no. 2 asparaginase therapy included 2500 IU/m2 pegaspargase IM on day 3 or native E. coli L-asparaginase 6000 IU/m2 IM on days 3, 5, 8, 10, 12, and 15. Additional therapies during delayed intensification no. 1 and no. 2 were: vincristine 1.5 mg/m2 IV on days 0, 7 and 14, dexamethasone 10 mg/m2 PO days 0-6, 14-20, doxorubicin 25 mg/m2 IV on days 0, 7 and 14; methotrexate 8 mg, 10 mg or 12 mg on days 0, 28, 35 (drugs, dose of IT are based on age), cyclophosphamide 1000 mg/m2 IV day 28, cytarabine IV or SC 75 mg/m2 days 29-32 , 36-39, and 60 mg/m2 day thioguanine PO 28-41.
LLA - signs and symptoms are often the result of one or more of the following:
Some signs and symptoms commonly seen in ALL may include the following:
Red blood cells (erythrocytes) - carry oxygen to the tissues and organs of the body:
These signs and symptoms may occur in other conditions and experiments and does not necessarily mean that a person has them all. Some patients with ALL may have other symptoms listed. Seek medical advice with your doctor is recommended for any associated symptoms. |
INFORMATIONThis blog is designed to provide information about acute lymphoblastic leukemia as well as treatment options and support for both patients and medical staff. All rights reserved to the group Asparaginase Pegilada. ArchivesCategories |